ANGPTL3 and familial hyperaldosteronism: Evinacumab is a fully human monoclonal antibody against ANGPTL3 and the only FDA-approved ANGPTL3 inhibitor for treating homozygous FH patients aged 12 years and older, as an adjunct to other lipid-lowering regimens (Fig. 1 and Table 1).